GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (FRA:6GJ) » Definitions » Gross Margin %

Glaukos (FRA:6GJ) Gross Margin % : 77.06% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Glaukos's Gross Profit for the three months ended in Dec. 2023 was €58.2 Mil. Glaukos's Revenue for the three months ended in Dec. 2023 was €75.5 Mil. Therefore, Glaukos's Gross Margin % for the quarter that ended in Dec. 2023 was 77.06%.

Warning Sign:

Glaukos Corp gross margin has been in long-term decline. The average rate of decline per year is -1.9%.


The historical rank and industry rank for Glaukos's Gross Margin % or its related term are showing as below:

FRA:6GJ' s Gross Margin % Range Over the Past 10 Years
Min: 59.23   Med: 79.62   Max: 86.78
Current: 75.99


During the past 11 years, the highest Gross Margin % of Glaukos was 86.78%. The lowest was 59.23%. And the median was 79.62%.

FRA:6GJ's Gross Margin % is ranked better than
85.43% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.54 vs FRA:6GJ: 75.99

Glaukos had a gross margin of 77.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Glaukos was -1.90% per year.


Glaukos Gross Margin % Historical Data

The historical data trend for Glaukos's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Gross Margin % Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.72 59.23 77.34 75.61 75.99

Glaukos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.82 75.55 75.00 76.28 77.06

Competitive Comparison of Glaukos's Gross Margin %

For the Medical Devices subindustry, Glaukos's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Glaukos's Gross Margin % falls into.



Glaukos Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Glaukos's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=219.3 / 288.59
=(Revenue - Cost of Goods Sold) / Revenue
=(288.59 - 69.302) / 288.59
=75.99 %

Glaukos's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=58.2 / 75.529
=(Revenue - Cost of Goods Sold) / Revenue
=(75.529 - 17.323) / 75.529
=77.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Glaukos  (FRA:6GJ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Glaukos had a gross margin of 77.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Glaukos Gross Margin % Related Terms

Thank you for viewing the detailed overview of Glaukos's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (FRA:6GJ) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Glaukos (FRA:6GJ) Headlines

No Headlines